---
title: Dr. Kevin Winthrop — drug & device company payments (CMS Open Payments 2024)
license: CC0-1.0
source: CMS Open Payments PY2024 (Sunshine Act)
---

# Dr. Kevin Winthrop — drug & device company payments (CMS Open Payments 2024)

CMS Open Payments PY2024 records for Dr. Kevin Winthrop (Infectious Disease, PORTLAND, OR, NPI 1679509525): $412,168 total across 108 payments from drug and device companies. Split by relevance: $411,183 promotional (marketing), $0 royalty/ownership, $985 research/other. Largest payers: GlaxoSmithKline, LLC. ($1,403,709), E.R. Squibb & Sons, L.L.C. ($105,435), AbbVie Inc. ($87,988). Source: Sunshine Act. CC0.

## Claims

### Total 2024 industry payments to Dr. Kevin Winthrop

**RECORDED.** In 2024, drug and device companies reported $412,168 in payments to Dr. Kevin Winthrop (Infectious Disease, PORTLAND, OR) across 108 payments.

Source: CMS Open Payments PY2024 (Sunshine Act) — https://openpaymentsdata.cms.gov/
Falsifier: A RECORD of measured/reported events (occurred=true) from CMS Open Payments PY2024 (Sunshine Act); superseded when CMS Open Payments PY2024 (Sunshine Act) publishes its next release.

### Payment composition: promotional vs royalty vs other

**INTERPRETATION.** Of that, $411,183 is promotional (meals, speaking, travel, consulting — a company marketing its products), $0 is royalty/ownership (income for inventing or owning something, not a prescribing conflict), and $985 is research/grants/other.

Source: Atlas Commons grouping of CMS nature-of-payment codes by patient relevance — https://care-atlas.ryanjhunter.workers.dev/
Falsifier: occurred=FALSE (a framing, not an event) and adjudged=FALSE (an in-house reading, not an authority's verdict) — the LOWEST-warrant claim here. A flat representation would render this identically to the official facts; the four-status does not.

### Largest paying companies (in-house ranking over CMS records)

**DERIVED.** Largest paying companies: GlaxoSmithKline, LLC. ($1,403,709), E.R. Squibb & Sons, L.L.C. ($105,435), AbbVie Inc. ($87,988), Genentech, Inc. ($81,388), Paratek Pharmaceuticals, Inc. ($42,889). The company names and per-payment amounts are CMS-recorded; the "largest" ranking and selection are an in-house aggregation, so adjudged=FALSE — CMS did not adjudge this ranking.

Source: Atlas Commons ranking over CMS Open Payments PY2024 by-company records — https://openpaymentsdata.cms.gov/
Falsifier: occurred=FALSE (a calculation, not an event) and adjudged=FALSE (a transparent in-house formula, not an authority's verdict — no external adjudicator). Reproduce it from its named inputs; falsified if the formula or inputs are wrong. Lower warrant than the adjudged figures above.

### What an Open Payments figure is — and is NOT

**INTERPRETATION.** A disclosed Open Payments amount is a publicly-reported financial relationship; it is not proof of wrongdoing and not evidence it changed patient care. It is not a rating of this physician.

Source: Sunshine Act transparency purpose; Atlas Commons L5 boundary — https://care-atlas.ryanjhunter.workers.dev/
Falsifier: occurred=FALSE (a framing, not an event) and adjudged=FALSE (an in-house reading, not an authority's verdict) — the LOWEST-warrant claim here. A flat representation would render this identically to the official facts; the four-status does not.

---

Every claim above carries a four-status warrant (RECORDED / MODELED / DERIVED / INTERPRETATION) and a named source you can re-fetch — this is a research object, not a flat fact. Structured: `https://care-atlas.ryanjhunter.workers.dev/payments/1679509525.jsonld`

## Data

### 2024 payment summary — Dr. Kevin Winthrop

CMS Open Payments PY2024. Nature split (INTERPRETATION) is Atlas Commons grouping, not a CMS category.

| Category | Amount | Warrant |
| --- | --- | --- |
| Total payments | $412,168 | RECORDED |
| Promotional | $411,183 | INTERPRETATION |
| Royalty / ownership | $0 | INTERPRETATION |
| Research / other | $985 | INTERPRETATION |

### Largest paying companies

In-house ranking over CMS records (DERIVED). Company names and amounts are CMS-RECORDED.

| Company | Amount paid (2024) | Warrant |
| --- | --- | --- |
| GlaxoSmithKline, LLC. | $1,403,709 | DERIVED |
| E.R. Squibb & Sons, L.L.C. | $105,435 | DERIVED |
| AbbVie Inc. | $87,988 | DERIVED |
| Genentech, Inc. | $81,388 | DERIVED |
| Paratek Pharmaceuticals, Inc. | $42,889 | DERIVED |

### Payments by CMS nature-of-payment code

CMS-reported nature codes (RECORDED).

| Nature | Code | Amount | Warrant |
| --- | --- | --- | --- |
| Consulting fees | 1 | $394,929 | RECORDED |
| Travel & lodging | 7 | $15,164 | RECORDED |
| Food & beverage | 6 | $1,090 | RECORDED |
| Grant | 14 | $985 | RECORDED |